Bodil Jönsson

Bodil Jönsson

Auto-generated profile, based on publicly available information

Bodil Jönsson

Clinical Bacteriology Section, Department of Infectious Medicine, University of Gothenburg, Göteborg, Sweden

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2016 in Science
Verified
Journal Article
Open access
PDF file
JBJosephine M. Bryant
Josephine M. Bryant
DGDorothy M. Grogono
Dorothy M. Grogono
DRDaniela Rodriguez-Rincon
Daniela Rodriguez-Rincon
IEIsobel Everall
Isobel Everall
KBKaren P. Brown
Karen P. Brown
RFR. Andres Floto
R. Andres Floto
Global spread of aggressive mycobacteria: Many mycobacteria, in addition to those causing leprosy and tuberculosis, are capable of infecting humans. Some can be particularly dangerous in patients suffering from immunosuppression or chronic disease, such as cystic fibrosis (CF). Bryant et al. observed clusters of near-identical isolates of drug-resistant Mycobacterium abscessus in patients reporting to CF clinics. The similarity of the isolates suggests transmission between patients, rather than environmental acquisition. Although this bacterium is renowned for its environmental resilience, the mechanism for its long-distance transmission among the global CF patient community remains a puzzle. Science , this issue p. 751

1 January 2015 in Journal of Cystic Fibrosis
Verified
Journal Article
Open access
TQTavs Qvist
Tavs Qvist
MGMarita Gilljam
Marita Gilljam
BJBodil Jönsson
Bodil Jönsson
DTDavid Taylor-Robinson
David Taylor-Robinson
SJSøren Jensen-Fangel
Søren Jensen-Fangel
TKTerese Lea Katzenstein
Terese Lea Katzenstein
Nontuberculous mycobacteria (NTM) are an emerging threat to cystic fibrosis (CF) patients but their epidemiology is not well described. In this retrospective observational study we identified all Scandinavian CF patients with a positive NTM culture from airway secretions from 2000 to the end of 2012 and used national CF databases to describe microbiological and clinical characteristics. During the 13-year period 157 (11%) CF patients were culture positive for NTM at least once. Mycobacterium abscessus complex (MABSC) (45%) and Mycobacterium avium complex (MAC) (32%) were the predominant species with geographical differences in distribution. Younger patients were more prone to MABSC (p<0.01). Despite treatment, less than one-third of MABSC patients with repeated positive cultures cleared their infection and a quarter had a lung transplant or died. NTM are significant CF pathogens and are becoming more prevalent in Scandinavia. MABSC and MAC appear to target distinct patient groups. Having multiple positive cultures despite treatment conveys a poor outcome.

1 March 2011 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
NKNahid Kondori
Nahid Kondori
MGMarita Gilljam
Marita Gilljam
ALAnders Lindblad
Anders Lindblad
BJBodil Jönsson
Bodil Jönsson
Edward R.B. MooreEdward R.B. Moore
Edward R.B. Moore
CWChristine Wennerås
Christine Wennerås
The black-pigmented fungusExophiala dermatitidisis considered to be a harmless colonizer of the airways of cystic fibrosis (CF) patients. The aim of this study was to establish the recovery rate ofE. dermatitidisin respiratory specimens from CF patients, transplant recipients, and subjects with other respiratory disorders in Sweden. Second, we wished to determine if particular clinical traits were associated withE. dermatitidiscolonization of the airways and the antifungal susceptibility profiles ofExophialastrains. Sputum and bronchoalveolar lavage samples (n= 492) derived from 275 patients were investigated.E. dermatitidiswas isolated in respiratory specimens from 19% (18/97) of the CF patients but in none of the other patient categories. All isolates were recovered after 6 to 25 days of incubation on erythritol-chloramphenicol agar (ECA) medium. Morphological and genetic analyses confirmed species identity. Pancreatic insufficiency was positively associated with the presence ofE. dermatitidisin sputum samples (P= 0.0198). Antifungal susceptibility tests demonstrated that voriconazole and posaconazole had the lowest MICs againstE. dermatitidis. In conclusion,E. dermatitidisis a frequent colonizer of the respiratory tract in CF patients in Sweden and appears to be associated with more advanced disease. WhetherE. dermatitidisis pathogenic remains to be elucidated.

1 July 2010 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
MGMarita Gilljam
Marita Gilljam
HSHenrik Scherstén
Henrik Scherstén
MSMartin Silverborn
Martin Silverborn
BJBodil Jönsson
Bodil Jönsson
AHAnnika Ericsson Hollsing
Annika Ericsson Hollsing

15 July 2008 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
PAPia Appelgren
Pia Appelgren
FFFilip Farnebo
Filip Farnebo
LDLeif Dotevall
Leif Dotevall
MSMarie Studahl
Marie Studahl
BJBodil Jönsson
Bodil Jönsson
BPBjorn Petrini
Bjorn Petrini
Background. In the tsunami catastrophe in Thailand in 2004, several thousand Swedish tourists were injured, with contaminated crush trauma of the legs being the main cause of injury among the survivors.

1 November 2013 in The International Journal of Tuberculosis and Lung Disease
Verified
Journal Article
Closed access
SHS. Hoffner
S. Hoffner
KÄK. Ängeby
K. Ängeby
ESE. Sturegård
E. Sturegård
BJB. Jönsson
B. Jönsson
AJA. Johansson
A. Johansson
JWJ. Werngren
J. Werngren
BACKGROUND: Pyrazinamide (PZA) is a key drug in the treatment of tuberculosis (TB), including multidrug-resistant TB. Drug susceptibility testing (DST) of Mycobacterium tuberculosis against PZA is not included in the World Health Organization's yearly proficiency testing. There is an increasing need to establish quality control of PZA DST. OBJECTIVE: To evaluate the performance of PZA DST and to introduce a quality assurance system for the test in Sweden. METHOD: Panels with PZA-susceptible and -resistant isolates were used in three rounds of proficiency testing in all five Swedish clinical TB laboratories and our reference laboratory. All laboratories used the MGIT 960 system. Minimum inhibitory concentrations (MICs) were determined and the pncA gene was sequenced to further characterise the 52 panel strains. RESULTS: Good agreement was seen between the phenotypic PZA DST and pncA sequence data, and MIC determination confirmed high levels of resistance. However, in contrast to other drugs, for which correct proficiency test results were observed, specificity problems occurred for PZA DST in some laboratories. CONCLUSIONS: In Sweden, using panel testing, differences were seen in the proficiency of TB laboratories in correctly identifying PZA susceptibility. Improved results were noted in the third round; PZA has therefore been included in yearly proficiency testing.